DexCom, Inc. (NASDAQ:DXCM) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC lifted its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.2% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,937,604 shares of the medical device company's stock after acquiring an additional 214,136 shares during the quarter. Geode Capital Management LLC owned about 2.54% of DexCom worth $664,056,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Brophy Wealth Management LLC purchased a new stake in shares of DexCom in the third quarter worth about $337,000. LRI Investments LLC lifted its position in DexCom by 225.0% during the 3rd quarter. LRI Investments LLC now owns 8,454 shares of the medical device company's stock worth $567,000 after acquiring an additional 5,853 shares in the last quarter. Groupama Asset Managment boosted its holdings in DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock worth $1,912,000 after acquiring an additional 31,358 shares during the period. Y Intercept Hong Kong Ltd grew its position in DexCom by 908.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 63,748 shares of the medical device company's stock valued at $4,274,000 after acquiring an additional 57,427 shares in the last quarter. Finally, Glass Jacobson Investment Advisors llc purchased a new stake in shares of DexCom during the third quarter valued at approximately $186,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

NASDAQ DXCM traded down $1.74 during trading hours on Friday, reaching $77.19. The company's stock had a trading volume of 2,954,447 shares, compared to its average volume of 3,884,590. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a 50-day simple moving average of $73.58 and a 200 day simple moving average of $84.99. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $30.15 billion, a PE ratio of 46.34, a PEG ratio of 2.46 and a beta of 1.12.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company's stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on DXCM. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Oppenheimer dropped their target price on DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Leerink Partners reduced their price target on DexCom from $90.00 to $87.00 and set an "outperform" rating for the company in a report on Friday, October 25th. Royal Bank of Canada dropped their price objective on DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Finally, JPMorgan Chase & Co. increased their target price on DexCom from $75.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $98.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.